Pfizer CEO Albert Bourla (L) and BioNTech CEO Ugur Sahin (AP Images)

Covid-19 roundup: FDA au­tho­rizes Pfiz­er/BioN­Tech vac­cine for 12- to 15-year-olds; No­vavax shares sink as com­pa­ny de­lays vac­cine time­line

Back-to-school sea­son could look much dif­fer­ent this year, as Pfiz­er and BioN­Tech’s Covid-19 vac­cine has be­come the first in the US to be au­tho­rized for chil­dren as young as 12 years old.

On Mon­day, the FDA ex­pand­ed its emer­gency use au­tho­riza­tion for the jab — which was orig­i­nal­ly OK’d for those 16 years and old­er — based on ef­fi­ca­cy da­ta from 190 ado­les­cents which showed their im­mune re­sponse to the vac­cine was at least as good as the re­sponse seen in old­er par­tic­i­pants.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.